Published in J Clin Endocrinol Metab on October 02, 2007
The biology and pathology of vitamin D control in bone. J Cell Biochem (2010) 1.03
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int (2010) 0.97
The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporos Int (2012) 0.84
Vitamin D metabolism in human bone marrow stromal (mesenchymal stem) cells. Metabolism (2013) 0.83
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (2006) 1.96
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab (2009) 1.35
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res (2005) 1.34
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab (2004) 1.15
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res (2013) 1.14
Osteosarcoma and teriparatide? J Bone Miner Res (2007) 1.14
The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin (2005) 1.11
Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin (2009) 1.02
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol (2005) 1.00
Prognostic utility of a semiquantitative spinal deformity index. Bone (2005) 0.99
PINP as an aid for monitoring patients treated with teriparatide. Bone (2010) 0.98
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin (2006) 0.97
Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res (2008) 0.94
Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int (2005) 0.94
Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab (2007) 0.91
First fractures among postmenopausal women with osteoporosis. J Bone Miner Metab (2010) 0.89
Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res (2010) 0.88
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan. Bone (2011) 0.88
Changes in vitamin D metabolites during teriparatide treatment. Bone (2012) 0.88
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. J Bone Joint Surg Am (2009) 0.85
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol (2005) 0.85
Application of genetic algorithm for discovery of core effective formulae in TCM clinical data. Comput Math Methods Med (2013) 0.84
Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone (2005) 0.84
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health (2013) 0.82
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone (2010) 0.81
Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opin (2011) 0.80
Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J (2010) 0.80
Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res (2009) 0.78
Comments on Initial experience with teriparatide in the United States. Curr Med Res Opin (2006) 0.77
Benefits and risks of raloxifene by vertebral fracture status. Curr Med Res Opin (2010) 0.76
Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis. J Bone Miner Metab (2011) 0.75
Teriparatide, osteoporosis, calcium, and vitamin D. N Engl J Med (2005) 0.75
New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status. J Clin Densitom (2006) 0.75